Employment Data - In December 2025, the U.S. added 50,000 non-farm jobs, which was below the market expectation of 65,000 and a decrease from the revised November figure of 64,000[3][15] - The unemployment rate fell to 4.4%, which was lower than market expectations, indicating a marginal improvement in the labor market[5][20] - Average hourly earnings increased by 3.8% year-on-year, surpassing market expectations[3][15] Labor Market Trends - The labor force participation rate remained stable at approximately 62.4%, while the unemployment rate decreased, suggesting a slight recovery in the labor market[5][20] - Permanent unemployment and first-time job seekers increased, while re-employment and temporary job seekers decreased, indicating a preference for hiring experienced workers[24][20] - Job openings in November were 7.146 million, down by approximately 303,000 from October, reflecting a slight easing in labor market tightness[6][38] Federal Reserve Outlook - The Federal Reserve is likely to maintain a wait-and-see approach regarding interest rate cuts, having already reduced rates by 75 basis points in 2025[7][46] - The Fed's decision to lower rates in December was influenced by rising unemployment risks, but the recent decline in unemployment may lead to a period of stable rates[7][46] - The Fed is expected to consider 1-2 additional rate cuts in 2026, primarily in the second half of the year[9][50]

- The Brain-Computer Interface (BCI) index has significantly increased by 84.11% since April 7, 2025, and by 18.28% since the beginning of 2026, attracting substantial market attention[3][14][15] - Public fund holdings in the BCI sector have been continuously declining since 2025, based on real-time estimates derived from public market information such as fund net value, holdings disclosure, and research activities[4][19][20] - ETF fund holdings in the BCI sector have shown a significant upward trend since December 2025, reflecting the growing popularity of index investment products in the A-share market[4][23][25] - The financing balance in the BCI sector has recently surged and then slightly declined, indicating a fluctuating investor sentiment towards the sector[4][24][26] - Companies like Beilu Pharmaceutical, Xiangyu Medical, and Guangdian Co., Ltd. have been the most frequently researched by institutions over the past three months[5][27][28] - Stocks such as Chuangxin Medical, Meihua Medical, and Xiangyu Medical have garnered the highest attention from influential users on the Xueqiu platform since December 20, 2025[5][29][31] - Major funds have flowed most into Chuangxin Medical, Meihua Medical, and Aipeng Medical since December 20, 2025, based on large and super-large order transactions[5][30][32] - Stocks like Saiwei Microelectronics, Hainan Haiyao, and Sainuo Medical have appeared on the Dragon and Tiger List since December 1, 2025, indicating active trading by major market players[5][33][34][35] - Companies such as Sainuo Medical, Chuangxin Medical, and Xiangyu Medical have seen the highest increases in shareholder numbers, suggesting potential future stock price risks[5][36][37]

Report Information - Report Title: 2025 December Price Data Review [2] - Date: January 9, 2026 [1] - Research Team: Fixed Income Research Team [2] - Analysts: Chen Xi, Wang Shuaizhong [3] Report Industry Investment Rating No information provided in the report. Core Viewpoints - The market consensus is to "end deflation" rather than "enter inflation," expecting PPI to reach 0% in H2 2026 and -0.6% for the whole year, but the report predicts prices will enter a "positive growth rate" [4]. - The report believes that factors such as anti - involution, policy lag, overseas fiscal expansion, and "dual - carbon" initiatives will drive prices up, and if PPI环比 can maintain 0.15 - 0.2%, price year - on - year increase to 2% is just a matter of time [5][6][7]. - The upward trend of prices will confirm the start of the economic cycle, and price recovery will form the fundamental basis for the upward movement of bond yields in 2026, with the 10 - year Treasury bond expected to fluctuate between 2 - 3% and the central value around 2.5% [7]. Summary by Related Catalogs Event - In December 2025, the PPI环比 was +0.2% and positive for three consecutive months, the first time since 2022 [3]. Market Expectation vs. Report Prediction - Market expectation: PPI year - on - year negative growth rate will converge in H1 2026, and then rise to around 0% in H2, with an annual PPI year - on - year of -0.6%, essentially expecting prices to level off [4]. - Report prediction: Prices will enter a positive growth rate, with the following logics [4][5][6]: - Anti - involution restricts price decline, and the market starts to raise prices in some categories. - The price inflection point lags behind the policy inflection point. In this weak recovery, the price inflection point lagged by 1 year, and prices started to stop falling and recover in September 2025. - Overseas fiscal expansion leads to currency depreciation and rising prices of physical assets. - "Dual - carbon" initiatives may lead to a new round of "capacity reduction." Impact on the Market - In 2025, the stagnation of "non - technology" sectors was due to the market's expectation of flat prices. As prices rise, the upward movement of the economic cycle may be confirmed [7]. - Price recovery will form the fundamental basis for the upward movement of bond yields in 2026. If PPI环比 can maintain 0.15 - 0.2%, the "potential inflation of 2.0%" will form the lower limit of the 10 - year Treasury bond, with the 10 - year Treasury bond expected to fluctuate between 2 - 3% and the central value around 2.5% [7]. Data Summary - **CPI Data in December 2025**: CPI环比 rose 0.2%, and CPI year - on - year rose 0.8%. Core CPI环比 rose 0.2%, and core CPI year - on - year rose 1.2%. Urban CPI year - on - year rose 0.9%, and rural CPI year - on - year rose 0.6% [9][18][31]. - **PPI Data in December 2025**: PPI环比 rose 0.2%, and PPI year - on - year fell 1.9%. Production materials PPI year - on - year fell 2.1%, and living materials PPI year - on - year fell 1.3% [11][23][31]. - **Industrial Producer Purchase Price Data in December 2025**: The price环比 rose 0.4%, and the price year - on - year fell 2.1% [28][31]. - **Industry Price Data in December 2025**: For example, the price decline of the coal mining and washing industry narrowed by 2.9 pct year - on - year compared with November; the price of the non - ferrous metal mining and dressing industry rose 24.0% year - on - year [33].

Group 1 - The report highlights that in 2025, the public quantitative strategies for the CSI 300, CSI 500, and CSI 1000 indices showed varying levels of excess returns, with the CSI 1000 enhanced products achieving the highest average excess return of 9.3% for the year [3][21] - The public quantitative CSI 300 enhanced products recorded an average excess return of 2.5% for 2025, with a quarterly excess return of 1.6% in Q4 [3][13] - The public quantitative CSI 500 enhanced products had an average excess return of 2.1% for 2025, with a quarterly excess return of 1.0% in Q4 [3][16] Group 2 - The report indicates that public quantitative dividend strategies achieved an average excess return of 4.2% in 2025, with top-performing products including Hai Fu Tong Dividend Preferred A and Guang Fa High Dividend Preferred A [4][29] - Public quantitative fixed income plus products had an average cumulative return of 4.9% in 2025, with leading products such as Fu Guo Xing Li Enhanced A and Fu Guo Feng Li Enhanced A [4][33] Group 3 - Private quantitative strategies for the CSI 300, CSI 500, and CSI 1000 indices outperformed public strategies, with the CSI 1000 enhanced products achieving an excess return of 15.1% for 2025 [5][40] - The private quantitative CSI 300 enhanced products recorded an excess return of 8.6% for the year, significantly higher than the public counterpart [5][37] - The private quantitative CSI 500 enhanced products achieved an excess return of 10.4% for 2025, again outperforming public strategies [5][38]

Investment Rating - The report assigns a "Buy" rating for the company, Zhongtong Bus (000957.SZ), marking its first coverage [1]. Core Insights - Zhongtong Bus is a long-established player in the bus industry, with a strong focus on expanding its overseas business and a solid backing from state-owned Shandong Heavy Industry Group. The company has seen a continuous recovery in profits since 2024, driven by its new energy and export initiatives [5][16]. - The company is expected to achieve revenues of 7.82 billion, 9.38 billion, and 11.88 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.67, 0.89, and 1.18 yuan. The current stock price corresponds to P/E ratios of 17.1, 12.9, and 9.8 for the same years [5][8]. Company Overview - Zhongtong Bus is one of the earliest bus manufacturers in China, with a diverse product range covering over 140 models, including electric, hybrid, and fuel-powered buses. The company has sold over 100,000 new energy buses globally [5][19]. - The company has a strong state-owned background, with Shandong Heavy Industry Group as its controlling shareholder, which provides robust support [20]. Industry Analysis - The bus industry in China is projected to grow at a CAGR of 13.0% from 2022 to 2024, with large and medium buses expected to grow at a CAGR of 18.2%. The demand for new energy buses is also on the rise, with significant growth in sales observed in 2024 and 2025 [6][39]. - The domestic market is benefiting from policies promoting the replacement of old buses, which is expected to significantly boost sales in 2024 [52]. Company Highlights - Since 2024, Zhongtong Bus has experienced a significant recovery in sales, particularly in large and medium buses, with a notable increase in the proportion of new energy vehicles. The company’s sales volume increased by 51.5% in 2024 [72]. - The company’s overseas sales have been growing rapidly, with a CAGR of 53.9% from 2021 to 2024, and a significant increase in new energy bus exports in the first half of 2025 [7][39]. Financial Summary and Valuation Metrics - The company’s revenue for 2023 was 4.24 billion yuan, with a projected growth to 5.73 billion yuan in 2024, reflecting a year-on-year increase of 35.1%. The net profit for 2024 is expected to be 249 million yuan, a significant recovery from previous years [8].

Investment Rating - The report provides a positive investment rating for the company, indicating it as a hidden champion in the medical care pad and dressing market, with strong ties to leading overseas medical companies [2]. Core Insights - The company, Aishalon, has been deeply engaged in the medical device industry for over 20 years, focusing on the research, production, and sales of disposable medical consumables used in rehabilitation care and medical protection [2][12]. - Aishalon is the largest manufacturer of medical care pads in China and ranks among the top ten exporters of medical dressings, with a rapidly growing sales scale and industry position [2][12]. - The company has established long-term stable partnerships with major clients and has obtained three international certifications, enhancing its market competitiveness [3][17]. Summary by Sections Company Overview - Aishalon specializes in disposable medical consumables, primarily in rehabilitation care and surgical infection control products, and has expanded its product line to include disinfection, home protection, and emergency protection [12]. - The company’s revenue structure is predominantly from overseas sales, with 94.71% of revenue coming from international markets in 2024, primarily from the US and Europe [33][34]. Industry Outlook - The global medical dressing market is projected to reach USD 23.5 billion by 2026, with the medical care pad market growing from CNY 5.08 billion in 2011 to CNY 20.996 billion in 2023 [3]. - The surgical drape market has shown stable growth, with an average annual growth rate of 4.5%, and is expected to continue this trend [3]. Financial Performance - The company anticipates total revenue of CNY 691.64 million in 2024, with a net profit of CNY 80.71 million and a gross margin of 22.91% [2][4]. - For 2025, the projected revenue growth is between 28.65% and 35.89%, with expected revenues ranging from CNY 889.82 million to CNY 939.87 million [2][34]. Competitive Position - Aishalon's core products, such as medical care pads, exhibit superior performance in key competitive indicators compared to peers, with a focus on continuous innovation and product quality [4][12]. - The company has established a robust patent portfolio, with 15 invention patents applied in its main business, contributing to its competitive edge [4][40].

Investment Rating - The industry investment rating is "Overweight" (maintained) [1] Core Insights - The report emphasizes the positive outlook for the AI industry, particularly in the context of the "AI + Manufacturing" initiative launched by the Ministry of Industry and Information Technology, which aims to promote deep integration of AI technology in manufacturing by 2027 [4] - The report highlights a potential recovery in domestic AIDC (Artificial Intelligence Data Center) bidding, indicating an increase in demand for domestic AI computing power [5] - Century Internet's financial performance shows significant growth, with a 21.7% year-on-year revenue increase in Q3 2025, suggesting a continued recovery in the AIDC sector [6] Summary by Sections AI Industry Development - The report notes that the government is actively promoting AI applications, which is expected to drive demand for domestic AI computing power [4] - The focus is on three core areas: AIDC, network endpoints, and computing endpoints, with specific recommended stocks for each segment [7] Financial Performance Indicators - Alibaba's capital expenditure for FY2026 Q2 reached 31.501 billion yuan, a year-on-year increase of 80.1%, indicating strong investment in AI cloud computing infrastructure [5] - Century Internet reported a total revenue of 2.58 billion yuan in Q3 2025, with adjusted EBITDA growing by 27.5% year-on-year, reflecting robust operational performance [6] Recommended Stocks - For AIDC data centers, recommended stocks include: Guanghuan New Network, Aofei Data, and others [7] - For AIDC liquid cooling and power supply, recommended stocks include: Yingweike and others [7] - For network endpoints, recommended stocks include: Zhongji Xuchuang, and others [7] - For computing endpoints, recommended stocks include: Oulutong, and others [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has seen a significant increase in sales of its luxury model, the Zun Jie S800, with a total of 3.73 million vehicles sold in December 2025, representing a year-on-year increase of 42.2%. However, the overall vehicle sales for the year were 384,100, reflecting a decline of 4.7% due to pressures in the traditional automotive sector. The forecast for 2026 and 2027 has been adjusted upwards, anticipating revenues of 514.9 billion (-0.7%), 801.4 billion (+131.8%), and 1,285.3 billion (+405.8%) respectively, with net profits expected to be -2.0 billion (-6.6%), 21.6 billion (+5.8%), and 77.7 billion (+40.0%) [6][7]. Summary by Relevant Sections Sales Performance - The Zun Jie S800 has achieved over 18,000 pre-orders within 175 days of its launch, with December 2025 deliveries expected to exceed 4,000 units. The model has consistently ranked first in the luxury sedan market priced above 700,000 yuan, surpassing competitors like Porsche and BMW [7]. Market Outlook - The luxury car market is expected to remain resilient, with strong consumer purchasing power. The upcoming models, including a standard and long-wheelbase MPV, are anticipated to further support sales in 2026. The approval of a 3.5 billion yuan capital increase will fund the production of 200,000 mid-to-high-end electric vehicles, enhancing the company's delivery capabilities [6][7]. Financial Projections - The company’s revenue is projected to grow significantly in the coming years, with a forecasted revenue of 801.4 billion in 2026, marking a 131.8% increase from 2025. The net profit is expected to turn positive in 2026, reaching 2.16 billion yuan [9][12].

Group 1: AI Chip Industry - The AI chip market in China is projected to grow from CNY 142.54 billion in 2024 to CNY 1,336.79 billion by 2029, driven by government support and technological advancements in the domestic AI industry [5][6]. - The domestic AI industry is categorized into three stages: the first focuses on self-sufficient AI computing, storage, and power chips; the second on chip manufacturing processes like wafer fabrication and packaging; and the third on foundational technologies such as materials and EDA [6][8]. - Key players in the AI chip market include Huawei, Cambricon, and Haiguang Information, with significant growth expected in AI storage and computing chips [6][7]. Group 2: Banking Sector - The banking sector is expected to see a steady growth of CNY 3.8 trillion in wealth management products by 2026, with a year-on-year increase of 11.46% [11]. - The demand for short-term wealth management products is rising, particularly non-current management products with a duration of less than one month, which are expected to yield annualized returns close to 3-year fixed deposit rates [12]. - Major banks like Citic Bank and Everbright Bank are recommended for their diversified product lines and strong research capabilities, while other banks such as SPDB and Bank of Beijing are also seen as beneficiaries [15]. Group 3: High-end Membrane Materials - The Chinese high-end membrane materials industry is poised for rapid growth due to geopolitical tensions and the shift of the global optoelectronic industry towards China, with a focus on breaking Japan's technological monopoly [19][20]. - Key domestic companies in this sector include Dongcai Technology and Jiemai Technology, which are expanding their production capacities and entering supply chains of major clients [20]. - The market for optical films and release films is characterized by high technical barriers, with significant opportunities for domestic manufacturers to capture market share from established foreign competitors [20][21]. Group 4: Semiconductor Equipment and Materials - The semiconductor materials and equipment sector is expected to accelerate its domestic capabilities due to increased geopolitical risks and supply chain security concerns, with a focus on self-sufficiency [29][30]. - Key areas for growth include photoresists and coating equipment, where domestic companies are beginning to establish a foothold in high-end markets [31][32]. - Beneficiaries in this sector include companies like Tongcheng New Materials and Changchuan Technology, which are positioned to capitalize on the growing demand for domestic semiconductor solutions [33]. Group 5: Animal Health Industry - The company is a leading player in the animal health sector, with a strong pipeline of vaccines, including the upcoming launch of a novel African swine fever vaccine, which is expected to significantly enhance profitability [34][36]. - The company has a robust R&D framework, with a focus on innovation and a diverse range of vaccine products, which positions it well for future growth [35]. - The anticipated market for the African swine fever vaccine could reach CNY 8.4 billion annually, providing a substantial growth opportunity for the company [36].

Group 1 - The semiconductor industry is expected to experience significant growth, with the domestic semiconductor index outperforming the CSI 300 index, showing a cumulative increase of 54.51% as of October 28, 2025, driven by factors such as national subsidies, AI computing demand, and domestic substitution [16][21]. - The AI chip market in China is projected to grow from 142.54 billion yuan in 2024 to 1,336.79 billion yuan by 2029, with a compound annual growth rate (CAGR) of 53.7% from 2025 to 2029, indicating a critical development opportunity for domestic AI chip manufacturers [42][44]. - The global GPU market is expected to grow from $77.39 billion in 2024 to $472.45 billion by 2030, with a CAGR of 35.19%, reflecting strong demand for AI computing [37][40]. Group 2 - The domestic AI chip industry is categorized into three stages: the first stage focuses on the self-sufficiency of computing, storage, and power chips; the second stage emphasizes the self-sufficiency of chip manufacturing processes; and the third stage targets the self-sufficiency of foundational hard technologies such as equipment materials and EDA [5][6]. - The demand for AI computing chips is driven by the rapid growth of generative AI applications, with NVIDIA's data center revenue increasing by 69% year-on-year to $44.1 billion in the first quarter of fiscal 2026, highlighting the accelerating demand for AI computing power [37][44]. - The semiconductor equipment sector is experiencing a significant increase in domestic production capacity, with the domestic semiconductor equipment localization rate expected to rise rapidly, particularly in dry etching and thin film deposition processes [6][15]. Group 3 - The report indicates that the advanced packaging technology, such as CoWoS, is expected to play a crucial role in the evolution of AI computing power, with domestic companies making significant advancements in this area [7][11]. - The semiconductor industry is witnessing a recovery in profitability, with the average gross margin and net profit margin for the semiconductor sector showing improvements in the first half of 2025 [36][34]. - The report highlights the importance of advanced wafer manufacturing as the physical foundation for AI chips, with a long-term demand for advanced foundry services expected to drive growth in this segment [7][11].